You might also like
Schrödinger, Inc. is a company that focuses on transforming the discovery of therapeutics and materials through its proprietary computational platform. The company develops and licenses a physics-based computational platform that accelerates the discovery of high-quality, novel molecules for drug development and materials applications. Schrödinger sells software solutions for molecular discovery and design, and engages in drug discovery collaborations and proprietary drug discovery programs.
-
Software Products and Services - Provides on-premise and hosted software, software maintenance, and professional services for molecular discovery and design, marketed to biopharmaceutical and industrial companies, academic institutions, and government laboratories globally.
-
Drug Discovery - Engages in collaborations with leading biopharmaceutical companies to advance drug discovery programs, generating revenue through milestone payments, option fees, and potential future royalties. The company also develops a pipeline of proprietary drug discovery programs, including its lead program SGR-1505, a MALT1 inhibitor for treating relapsed or refractory B-cell lymphomas.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Ramy Farid, Ph.D. ExecutiveBoard | President and Chief Executive Officer | Board Member at Structure Therapeutics, Inc. | Ramy Farid has been with Schrödinger for over 20 years, serving as President since 2008 and CEO since 2017. He has led the company’s computational drug discovery efforts and strategic growth. | View Report → |
Geoffrey Porges, MBBS Executive | Executive Vice President and Chief Financial Officer | None | Geoffrey Porges joined SDGR in 2022 as CFO. He has extensive experience in financial leadership and biopharmaceutical research, previously holding senior roles at SVB Securities and Alliance Bernstein. | |
Margaret Dugan, M.D. Executive | Chief Medical Officer | Board Member at BeiGene, Ltd. | Margaret Dugan joined SDGR in 2023. She oversees clinical development and regulatory strategy for SDGR’s pipeline, including advancing clinical-stage assets like SGR-1505 and SGR-2921. | |
Patrick Lorton Executive | Chief Operating Officer, Software | None | Patrick Lorton has been with SDGR since 2006, holding various technical and leadership roles. He became COO in 2024, overseeing software operations and engineering. | |
Yvonne Tran Executive | Executive Vice President, Chief Legal Officer, and Chief People Officer | None | Yvonne Tran has been with SDGR since 2010, progressing from General Counsel to her current dual leadership roles. She oversees legal and human resources functions. | |
Arun Oberoi Board | Board Member | Chairman of SUSE S.A.; Board Member at Proofpoint, Talend, Deeplite; Advisor at Paymentus | Arun Oberoi joined SDGR’s board in 2022. He has extensive leadership experience in technology and software, including roles at Red Hat and Micromuse. | |
Gary Ginsberg Board | Board Member | Board Member at Townsquare Media, Inc. | Gary Ginsberg joined SDGR’s board in 2020. He has extensive experience in corporate communications and marketing, with leadership roles at SoftBank, Time Warner, and News Corporation. | |
Gary Sender Board | Board Member | Board Member at Harmony BioSciences and iBio, Inc. | Gary Sender joined SDGR’s board in 2019. He has extensive financial expertise, having served as CFO at Nabriva Therapeutics and Synergy Pharmaceuticals. | |
Michael Lynton Board | Chairman of the Board | Chairman of Snap Inc. and Warner Music Group; Board Member at Ares Management | Michael Lynton has been Chairman of SDGR’s board since 2018. He has a distinguished career in media and technology, including leadership roles at Snap and Warner Music Group. | |
Nancy Thornberry Board | Board Member | Chair of R&D at Kallyope, Inc.; Board Member at Denali Therapeutics and Vertex Pharmaceuticals | Nancy Thornberry joined SDGR’s board in 2019. She has a strong background in life sciences and drug development, previously serving as CEO of Kallyope. |
- "Given the significant decrease in drug discovery revenue this quarter compared to the same period last year , can you provide more clarity on the specific factors contributing to this decline and how you plan to address them going forward?"
- "With the lower gross margin in the software segment this quarter, partly due to the initial revenue recognized in the Gates predictive tox collaboration , how do you anticipate gross margins evolving in the coming quarters, especially considering the shift towards hosted contracts?"
- "Can you elaborate on the potential risks associated with the timing of the milestones that led to the reduction in drug discovery revenue guidance for the year , and how confident are you that these milestones will be achieved in the next fiscal year?"
- "Operating expenses have increased compared to last year, primarily due to higher R&D expenses , how do you plan to manage operating costs moving forward to achieve operating leverage, especially in light of the ongoing investments in your proprietary programs?"
- "As the proportion of hosted contracts continues to grow in your software business , how are you addressing potential customer concerns about data security and integration, and what impact might this shift have on your renewal rates and average contract values?"
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
XTAL BioStructures, Inc. | 2022 | Schrödinger acquired XTAL BioStructures, Inc. in 2022 for a total cash purchase price of approximately $7.429 million, structured with various allocations including cash, receivables, PPE, intangible assets, and goodwill, directly supporting its structural biology capabilities. The acquisition strategically enhances its drug discovery programs by providing services such as protein production, purification, and X-ray crystallography, enabling computationally validated protein structures for lead optimization. |
Recent press releases and 8-K filings for SDGR.
- Quorum established with 52,556,775 common shares and 9,164,193 limited shares; four Class II directors elected, advisory vote on executive compensation approved, and KPMG LLP ratified as independent auditor.
- CEO Rami Farid highlighted 1,800 customers and the hybrid physics–machine learning computational platform driving drug and materials discovery.
- Announced Phase 1 data for SGR1505 in advanced relapsed/refractory B cell malignancies showing favorable safety and preliminary efficacy, with FDA discussions on the recommended Phase 2 dose planned later in 2025.
- Confirmed upcoming H2 2025 data presentations for SGR2921 (CDC7 inhibitor in AML/MDS) and SGR3515 (advanced solid tumors), alongside continued platform enhancements and collaboration expansions.
- Reviewed Phase I data in 49 heavily pretreated relapsed/refractory B-cell malignancy patients; no dose-limiting toxicities observed and a favorable safety profile with 43% experiencing treatment-related AEs; asymptomatic bilirubin increases occurred in patients with UGT1A1 polymorphisms.
- Pharmacodynamics confirmed ≈90% inhibition of T-cell derived IL-2 at steady state for doses ≥150 mg QD and all BID regimens, with more sustained suppression on the BID schedule.
- Among 45 efficacy-evaluable patients, the overall response rate was 22%, including responses in 3/17 CLL, 5/5 Waldenström’s macroglobulinemia, 1/5 marginal zone lymphoma and 1/4 ABC-DLBCL; one Waldenström’s patient remains on treatment for nearly two years.
- Dose escalation is complete (300 mg QD and 150 mg BID); next steps include an FDA meeting to set the Phase II recommended dose and plans to explore combinations with BTK and BCL2 inhibitors.
- New CFO Appointment: The newly appointed CFO, who joined in 2024 from Morgan Stanley, outlined his broader role and focus on business development and strategic finance to drive the company’s initiatives, including software growth.
- Clinical Pipeline and Program Updates: The company shared progress on its proprietary assets, highlighting the Phase I study of the fifteen oh five MALT1 inhibitor—demonstrating safety, tolerability, and preliminary efficacy in relapsed/refractory B-cell malignancies—with plans to expand follow-up and combo studies.
- Revenue Performance and Strategic Partnerships: Schrodinger reported strong Q1 revenue performance with notable 46% year-on-year growth in software revenue and emphasized strategic deals, such as the $150 million Novartis agreement, to support its integrated digital chemistry platform and future guidance of 10%–15% revenue growth.
- Richie Jain has been appointed as Executive Vice President, Chief Financial Officer, and Treasurer effective May 16, 2025 with a base salary of $535,000 and eligibility for a prorated 55% bonus in 2025.
- The Employment Agreement includes equity awards of 18,750 stock options and 9,375 restricted stock units subject to vesting schedules, along with standard executive benefits and indemnification provisions.
- The filing also notes the transition of outgoing CFO Geoffrey Porges, who will serve as an advisor through June 6, 2025, ensuring a smooth changeover.
- Schrödinger, Inc. restructured its operations on May 19, 2025, to reduce its workforce and implement focused cost reductions to improve cash burn rate and efficiency.
- The Company reduced its headcount by approximately 60 employees (7%), with restructuring costs estimated at $3 million and projected annual operating expense savings of about $30 million.
- Integrated Business Model: Schrodinger leverages a platform combining physics‐based methods and AI to drive software licensing, drug discovery collaborations, and its proprietary development programs.
- Strong Collaborations and Performance: The company highlighted key partnerships with Novartis, Lilly, and Otsuka, noting Q1 2025 revenue of nearly $60 million, with $48.8 million in software and $10.7 million in drug discovery revenue.
- Positive Forward Guidance: Management expects software revenue growth of 10%–15% this year and anticipates increased recognition from drug discovery collaborations and advances in predictive toxicology assays.
- Q1 2025 Total Revenue reached $59.6 million (up 63% YoY), driven by robust performance in software ($48.8 million, up 46%) and drug discovery ($10.7 million, up 237%) .
- The quarter saw a widened net loss of $59.8 million versus $54.7 million in Q1 2024, reflecting continued investments .
- The company reaffirmed its full-year guidance, targeting software revenue growth of 10%-15% and drug discovery revenue between $45 million and $50 million amid macroeconomic challenges .
- Advancements in the predictive toxicology initiative, leveraging a blend of physics and machine learning, are expected to enhance both collaborative and proprietary programs .